158 related articles for article (PubMed ID: 12572995)
1. ICL670A: preclinical profile.
Nick H; Wong A; Acklin P; Faller B; Jin Y; Lattmann R; Sergejew T; Hauffe S; Thomas H; Schnebli HP
Adv Exp Med Biol; 2002; 509():185-203. PubMed ID: 12572995
[No Abstract] [Full Text] [Related]
2. Development of tridentate iron chelators: from desferrithiocin to ICL670.
Nick H; Acklin P; Lattmann R; Buehlmayer P; Hauffe S; Schupp J; Alberti D
Curr Med Chem; 2003 Jun; 10(12):1065-76. PubMed ID: 12678677
[TBL] [Abstract][Full Text] [Related]
3. ICL670A: a new synthetic oral chelator: evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture.
Hershko C; Konijn AM; Nick HP; Breuer W; Cabantchik ZI; Link G
Blood; 2001 Feb; 97(4):1115-22. PubMed ID: 11159545
[TBL] [Abstract][Full Text] [Related]
4. Deferasirox--an oral agent for chronic iron overload.
Vanorden HE; Hagemann TM
Ann Pharmacother; 2006 Jun; 40(6):1110-7. PubMed ID: 16735647
[TBL] [Abstract][Full Text] [Related]
5. Treating iron overload: the state of the art.
Hershko C
Semin Hematol; 2005 Apr; 42(2 Suppl 1):S2-4. PubMed ID: 15846582
[No Abstract] [Full Text] [Related]
6. Clinical pharmacology of deferasirox.
Tanaka C
Clin Pharmacokinet; 2014 Aug; 53(8):679-94. PubMed ID: 24996374
[TBL] [Abstract][Full Text] [Related]
7. In brief: Jadenu--a new formulation of deferasirox for iron overload.
Med Lett Drugs Ther; 2016 Apr; 58(1493):e56. PubMed ID: 27101213
[No Abstract] [Full Text] [Related]
8. Deferasirox pharmacokinetic evaluation in β-thalassaemia paediatric patients.
Allegra S; Cusato J; De Francia S; Pirro E; Massano D; Piga A; D'Avolio A
J Pharm Pharmacol; 2017 May; 69(5):525-528. PubMed ID: 27230486
[TBL] [Abstract][Full Text] [Related]
9. Exjade (ICL 670): A new oral iron chelator.
Agarwal MB
J Assoc Physicians India; 2006 Mar; 54():214-7. PubMed ID: 16800349
[TBL] [Abstract][Full Text] [Related]
10. Do we need more iron-chelating drugs?
Kontoghiorghes GJ
Lancet; 2003 Aug; 362(9382):495-6. PubMed ID: 12927446
[No Abstract] [Full Text] [Related]
11. Preclinical and clinical development of deferitrin, a novel, orally available iron chelator.
Donovan JM; Plone M; Dagher R; Bree M; Marquis J
Ann N Y Acad Sci; 2005; 1054():492-4. PubMed ID: 16339704
[TBL] [Abstract][Full Text] [Related]
12. Deferasirox: pharmacokinetics and clinical experience.
Galanello R; Campus S; Origa R
Expert Opin Drug Metab Toxicol; 2012 Jan; 8(1):123-34. PubMed ID: 22176640
[TBL] [Abstract][Full Text] [Related]
13. Deferasirox effectively decreases iron burden in patients with double heterozygous HbS/β-thalassemia.
Voskaridou E; Plata E; Douskou M; Sioni A; Mpoutou E; Christoulas D; Dimopoulou M; Terpos E
Ann Hematol; 2011 Jan; 90(1):11-5. PubMed ID: 20661572
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, characterization and in vitro anticancer evaluations of two novel derivatives of deferasirox iron chelator.
Salehi S; Saljooghi ASh; Shiri A
Eur J Pharmacol; 2016 Jun; 781():209-17. PubMed ID: 27090924
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics, metabolism, and disposition of deferasirox in beta-thalassemic patients with transfusion-dependent iron overload who are at pharmacokinetic steady state.
Waldmeier F; Bruin GJ; Glaenzel U; Hazell K; Sechaud R; Warrington S; Porter JB
Drug Metab Dispos; 2010 May; 38(5):808-16. PubMed ID: 20097723
[TBL] [Abstract][Full Text] [Related]
16. A 5-year follow-up in deferasirox treatment: improvement of cardiac and hepatic iron overload and amelioration in cardiac function in thalassemia major patients.
Cassinerio E; Roghi A; Orofino N; Pedrotti P; Zanaboni L; Poggiali E; Giuditta M; Consonni D; Cappellini MD
Ann Hematol; 2015 Jun; 94(6):939-45. PubMed ID: 25563596
[TBL] [Abstract][Full Text] [Related]
17. Deferasirox: A comprehensive drug profile.
Kabil MF; Nasr M
Profiles Drug Subst Excip Relat Methodol; 2024; 49():1-18. PubMed ID: 38423705
[TBL] [Abstract][Full Text] [Related]
18. Deferasirox for the treatment of iron overload in non-transfusion-dependent thalassemia.
Taher AT; Temraz S; Cappellini MD
Expert Rev Hematol; 2013 Oct; 6(5):495-509. PubMed ID: 24083402
[TBL] [Abstract][Full Text] [Related]
19. Deferasirox.
Stumpf JL
Am J Health Syst Pharm; 2007 Mar; 64(6):606-16. PubMed ID: 17353569
[TBL] [Abstract][Full Text] [Related]
20. Thalassemia: cardiac iron and chelators.
Gaur A
Indian Pediatr; 2012 Apr; 49(4):268-9. PubMed ID: 22565070
[No Abstract] [Full Text] [Related]
[Next] [New Search]
